GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omeros Corp (NAS:OMER) » Definitions » Net Change in Cash

Omeros (Omeros) Net Change in Cash : $-3.90 Mil (TTM As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Omeros Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Omeros's Net Change in Cash for the three months ended in Dec. 2023 was $-23.54 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.90 Mil.

Omeros Net Change in Cash Historical Data

The historical data trend for Omeros's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omeros Net Change in Cash Chart

Omeros Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.78 7.42 90.31 -89.80 -3.90

Omeros Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -134.52 -7.18 2.77 24.04 -23.54

Omeros Net Change in Cash Calculation

Omeros's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=74.726+27.454+-106.084+0
=-3.90

Omeros's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-34.825+116.243+-104.953+0
=-23.54

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.90 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Omeros Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Omeros's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Omeros (Omeros) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omeros Corp (NAS:OMER) » Definitions » Net Change in Cash
Comparable Companies
VSTM ALDX PBYI CRMD INMB GOSS SYRS DRTS XOMA ZURA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XKRX:068270 BNTX ALNY
Traded in Other Exchanges
3O8:Germany
Address
201 Elliott Avenue West, Seattle, WA, USA, 98119
Website
https://www.omeros.com
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
Executives
Demopulos Gregory A Md director, 10 percent owner, officer: Chairman, CEO & President 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Demopulos Peter A Md director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Arnold C Hanish director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Thomas J. Cable director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Diana T. Perkinson director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Michael A Jacobsen officer: VP Finance and CAO 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Kurt Zumwalt director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Peter B Cancelmo officer: See Remarks 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Thomas F. Bumol director 201 ELLIOT AVENUE WEST, SEATTLE WA 98119
Marcia S. Kelbon officer: VP Patent and General Counsel 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Ray Aspiri director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Hood Leroy E. Md Phd director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Rajiv Shah director C/O ARCADIA BIOSCIENCES, INC., 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Jean-philippe Tripet director 1420 FIFTH AVENUE, SUITE 2600, SEATTLE WA 98101-2347

Omeros (Omeros) Headlines

From GuruFocus

Omeros Announces Results From Nearly Three-Year Follow-up of Patients in Phase 2 IgA Nephropathy Trial

By Business Wire Business Wire • 11-05-2021

Omeros Announces Journal of Clinical Oncology Publication Detailing Pivotal Trial Results for Narsoplimab in HSCT-TMA

By Business Wire Business Wire • 04-20-2022

Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2021

By Business Wire Business Wire • 11-04-2021

Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2022

By Business Wire Business Wire • 11-04-2022

Omeros' Narsoplimab Stabilized Kidney Function and Reduced Urinary Complement Proteins in a Patient with IgA Vasculitis

By Business Wire Business Wire • 11-05-2021

FDA Grants Orphan Drug Designation to Omeros' MASP-3 Inhibitor OMS906 for Treatment of Paroxysmal Nocturnal Hemoglobinuria

By Business Wire Business Wire • 07-29-2022

Omeros Corporation Announces Availability on Its Website of Materials Accompanying Presentations of OMS906 Data at the 2023 European Hematology Association Congress

By Business Wire Business Wire • 06-12-2023

Omeros Announces Webcast Details for Annual Meeting of Shareholders

By Business Wire Business Wire • 06-21-2023

Omeros Confirms Submission of Response to FDA Regarding the BLA for Narsoplimab in the Treatment of HSCT-TMA

By Business Wire Business Wire • 01-19-2022

Omeros Corporation to Announce First Quarter Financial Results on May 10, 2022

By Business Wire Business Wire • 05-04-2022